HUMA Earnings Prediction
The chart below shows how HUMA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HUMA sees a -1.27% change in stock price 10 days leading up to the earnings, and a +5.66% change 10 days following the report. On the earnings day itself, the stock moves by +1.93%. This data can give you a slight idea of what to expect for the next quarter's release.
HUMA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.33
-32.00%
-31.25%
No Data Available
HUMA Earnings Analysis
Humacyte, Inc. Common Stock Corporation (HUMA.O) Earnings Conference Call
Positive
FDA Review and Market Preparation: The FDA review of our ATEV BLA in vascular trauma is still ongoing, the entire Humacyte team continues to engage in commercial preparation to support our planned U.S. market launch, if approved.
NTAP Application Submission: We submitted our new technology add-on payment, or NTAP, application to the Centers for Medicare and Medicaid Services in early October.
Phase 3 Trial Results: Positive top-line results and subgroup analyses from our V007 Phase 3 clinical trial of the ATEV in hemodialysis were recently presented at Kidney Week, and this presentation was followed by a webinar of key opinion leaders in dialysis who discussed the implications of the study.
Patent Approval for BVP Candidate: Regarding our pipeline, the U.S. Patent Office allowed a patent covering the design and the composition of the biovascular pancreas, or BVP, product candidate for treating Type 1 diabetes.
Stock Offering Completion: We completed a registered direct offering of Humacyte stock of approximately $30 million.
Negative
No Revenue Reported: No revenue was reported for the third quarter of either 2024 or 2023, and no revenue for the nine months ended September 30, 2024 and 2023.
R&D Expense Decrease: Research and development expenses were $22.9 million for the third quarter of 2024, a slight decrease compared to $23.8 million for the second quarter of 2024.
Quarterly Net Loss Comparison: Net loss was $39.2 million for the third quarter of 2024, compared to $56.7 million for the second quarter of 2024.
Net Loss Increase Factors: The year-over-year increase in net loss resulted primarily from the non-cash remeasurement of the contingent earn-out liability associated with the company's 2021 going public transaction.
Cash Usage Comparison: Total net cash used was $9.9 million for the first nine months of 2024, compared to net cash used of $49.4 million for the first nine months of 2023.
HUMA FAQs
How does HUMA typically perform around its earnings report dates?
Is Humacyte, Inc. (HUMA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HUMA Earning Call Sentiment
Humacyte, Inc. (HUMA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
HUMA.O
8.75%Positive
The earnings call summary indicates financial challenges with a significant net loss increase and no revenue reported. Although cash utilization improved, the reliance on external funding and a $30 million stock offering signals financial instability. The FDA review delays add regulatory risks, and increased expenses raise concerns. The Q&A section reflects uncertainties in FDA discussions and potential delays in product approval. While cash reserves were bolstered, the financial health and competitive pressures suggest a negative sentiment, likely leading to a stock price decline in the short term.
